Article

Obesity is linked to aggressive prostate cancer

Obese men with prostate cancer are more likely to have aggressive tumors and to experience cancer recurrence after surgery compared with men of normal weight or those who are overweight but not obese, according to two new studies.

Related Videos
1 expert is featured in this series.
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
2 experts are featured in this series.
Key Benefits of PET in ccRCC Risk Stratification
4 experts in this video
Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
2 experts are featured in this series.
Early Detection of ccRCC
1 expert is featured in this series.
Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Study findings highlight gender gaps in oncology authorship and citation
NMIBC Treatment Decisions in the Age of BCG Shortages
NMIBC Treatment Decisions in the Age of BCG Shortages
Current Standards of Care and Shifting Strategies in NMIBC
Current Standards of Care and Shifting Strategies in NMIBC
Related Content
A. Oliver Sartor, MD
June 2nd 2025

Long-term data support radium-223 safety in mCRPC

Benjamin P. Saylor
“Prior taxanes did not increase reported hematological adverse events during treatment with Ra-223,” the investigators reported.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Aditya Dhanawat, MBBS, MD, DM
June 2nd 2025

RCT compares platinum/5-FU, platinum/paclitaxel in high-risk penile cancer

Benjamin P. Saylor
“On the intention-to-treat efficacy analysis...the median PFS was numerically higher for the paclitaxel arm," said Aditya Dhanawat, MBBS, MD, DM.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
June 1st 2025

NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC

Benjamin P. Saylor
The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.
Nivolumab/ipilimumab continues to show improved survival, durable response in aRCC
June 1st 2025

Nivolumab/ipilimumab continues to show improved survival, durable response in aRCC

Hannah Clarke
"This final analysis of this study continues to support nivo+ipi as a standard of care for patients with untreated RCC," says Robert J. Motzer, MD.
© 2025 MJH Life Sciences

All rights reserved.